Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Desoximetasone Ointment USP, 0.25%. Desoximetasone Ointment is used in relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. The drug will be manufactured at the group’s Topical manufacturing facility at Ahmedabad.
The group now has more than 149 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
